Spero Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Spero Therapeutics, Inc. has issued its 2026 proxy statement detailing proposals for director elections, executive compensation, and a significant increase in authorized common stock.
NASDAQ
DEFA14A: Spero Therapeutics Sets Date for 2025 Annual Meeting, Seeks Stockholder Votes on Key Proposals
Spero Therapeutics is holding its annual stockholder meeting on June 12, 2025, and is soliciting votes on the election of directors, ratification of the company's accounting firm, executive compensation, and an amendment to the stock incentive plan.
NASDAQ
Spero Therapeutics is holding its 2025 annual meeting virtually on June 12, 2025, to elect directors, ratify the selection of its accounting firm, approve executive compensation, and amend its stock incentive plan.
NASDAQ
DEFA14A: Spero Therapeutics to Hold Annual Meeting on May 29, 2024, Stockholders to Vote on Key Proposals
Spero Therapeutics' stockholders will vote on the election of directors, ratification of the accounting firm, executive compensation, and an amendment to the stock incentive plan at the upcoming annual meeting.
NASDAQ
Spero Therapeutics is holding its 2024 annual meeting of stockholders on May 29, 2024, to elect directors, ratify the selection of its accounting firm, approve executive compensation, and amend its stock incentive plan.